
Search
Filter Results
Displaying 11–20 of 688 for “retinitis clinical trial”
-
Dec 21, 2018
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
-
Nov 8, 2023
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
The company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
May 17, 2022
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Apr 10, 2025
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.
-
Dec 20, 2024
The company is also planning to conduct the clinical trial at sites in the EU.
-
Dec 2, 2022
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
May 6, 2019
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
In a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
Dec 4, 2018
ProQR Receives FDA Authorization to Launch Clinical Trial for USH2A Therapy
ProQR, a biotech in the Netherlands developing therapies for rare diseases, has received authorization from the US Food and Drug Administration to launch a Phase I/II clinical trial for QR-421a, its treatment targeting mutations in exon 13 of the USH2A gene.
-
May 13, 2025
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Apr 12, 2024
Phase 3 Clinical Trial of NAC Launched for RP Patients
The drug is thought to work independent of the mutated gene causing RP.